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ABSTRACT 
Objective.  To address the lack of outcome data concerning pregnancies exposed to the 
interleukin-1 (IL-1) inhibitors prior to conception in both men and women, during pregnancy 
and breast feeding.  
Methods.  Retrospective data were collected from members of the International Society 
for Systemic Autoinflammatory diseases and collated in a single center.   A uniform data 
collection sheet was used to obtain standardized data including maternal age and diagnosis, 
type and duration and response to IL-1 blockade, and pregnancy duration, delivery, mode of 
feeding and neonatal development.   
Results.  There were 31 maternal-exposed pregnancies from seven countries and we 
report the first data on paternal exposure; six to anakinra and 5 to canakinumab, with no 
negative outcomes.  We also report the first data on canakinumab exposed pregnancies; eight 
pregnancies which resulted in the delivery of 7 healthy infants of normal gestational age and 
birthweight.  There were 23 anakinra-exposed pregnancies resulting in the birth of 21 healthy 
infants, and one baby with unilateral renal agenesis and ectopic neurohypophysis.   
There were two first trimester miscarriages affecting a mother with active disease. There were 
no serious neonatal infections. Fourteen infants were breast fed with no complications. There 
were no reports of developmental delay, with follow-up of up to 10 years (median 18 months).   
Conclusion.  This series substantially increases the published experience of IL-1 blockade 
and reproduction including the first data on canakinumab and on paternal exposure to these 
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agents.  Data are generally reassuring, although the case of renal agenesis is the second 
reported in an anakinra-exposed pregnancy.   
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The first interleukin-1 inhibitor was licensed for use in rheumatoid arthritis in 2001, however, 
these agents have been most dramatically effective in the systemic autoinflammatory diseases 
(SAIDS)(1). These diseases generally present during childhood, (2) and with better disease 
recognition and diagnostics, their apparent incidence is rising and diagnostic delay is decreasing.  
Treatment with interleukin-1 (IL-1) antagonists completely controls symptoms in a number of 
SAIDS, with dramatic and sustained improvement in quality of life.(3)  For patients with 
genetically determined SAIDS disease, these life-transforming therapies are likely to be required 
lifelong and many are unable to stop the medication prior to conception or during pregnancy. 
More than a decade after the first reported use of IL-1 inhibition in SAIDS,(4) an increasing 
number of patients are reaching reproductive age and contemplating starting a family. For 
patients with well controlled disease and an expectation of a near normal duration and quality 
of life, information concerning their fertility and the potential risks to themselves and their 
children is of enormous importance.  However, even compared to other biologic medications, 
few data on the safety of IL-1 antagonist are available in relation to conception, pregnancy or 
breast feeding. This paucity of sound evidence is recognized in a recent international consensus 
document on use of antirheumatic drugs around pregnancy (5)  whilst this may reflect the rarity 
of SAIDS, the lack of data is compounded by exclusion of reproductively active subjects from drug 
trials, and by manufacturers discouraging the use of biologic agents in women contemplating 
pregnancy.  As men must also use contraception when participating in drug trials, there is a total 
lack of published data on the health of offsprings born to fathers receiving IL-1 antagonists.    
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Currently there are three IL-1 antagonists, anakinra (Kineret®, Sobi), canakinumab (Ilaris®, 
Novartis) and rilonacept (ARCALYST®, Regeneron Pharmaceuticals) and their characteristics are 
summarized in Table 1.    
To create a much needed evidence base to inform decision making for our patients, the 
international autoinflammatory community has come together to provide this data with 
suggested recommendations for managing conception and pregnancy in this group of patients 
on these medications.  
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PATIENTS AND METHODS  
A request for data was made in 2012 to members of the International Society for Systemic 
Autoinflammatory diseases.  A data collection sheet was used to obtain standardized 
retrospective data including maternal age, autoinflammatory syndrome diagnosis, obstetric 
history, type and duration of IL-1 blockade, biochemical and clinical response to IL-1 inhibition, 
pregnancy duration and delivery mode.  Infant data for APGAR (Appearance, Pulse, Grimace, 
Activity and Respiration) score, birth weight, congenital abnormalities, development, breast 
feeding status and age at last follow-up were collected.  The study was approved by the Royal 
Free NHS Trust ethical committee, and consent was obtained by the treating physician and 
indicated on the data collection sheet. Paternal exposure data were collected by retrospective 
review of case notes.   
 
RESULTS 
We identified 43 pregnancies exposed to IL-1 inhibitors from seven countries, including 14 
canakinumab-exposed pregnancies, of which 8 were maternal (Table 2) and 29 anakinra-exposed 
pregnancies of which 23 were maternal (Table 3).  We report the first data on paternal exposure 
to anakinra (n=6) and canakinumab (n=5) (Table 4). We report the outcome of 14 neonates breast 
fed by mothers taking anakinra (n=10) or canakinumab (n=4) for up to ten months duration, with 
no reported serious infections (Tables 2 and 3). There were no developmental abnormalities with 
median follow-up of 18 months (range 1 week to 10 years).  There were no cases of rilonacept 
use in pregnancy.  
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In keeping with the known favorable safety and efficacy profiles of these medications, there were 
no reported serious infections in the mothers nor neonates and disease was in complete clinical 
and biochemical remission in all but three cases (detailed below) 
 
Canakinumab  
Eight pregnancies, from seven women, were exposed to canakinumab and resulted in seven live 
births (Table 2).  A single case of miscarriage occurred at six weeks to a 26-year-old mother with 
refractory Cogan Syndrome, with only a partial clinical and biochemical response to canakinumab 
at a dose of 150mg monthly.  This was her second miscarriage, the first occurring on anakinra the 
previous year. Of the seven live births, mean maternal age was 24 years (range 16-32 years), all 
were in complete clinical and biochemical remission for CAPS (n=4), FMF (n=2), and one case of 
unexplained inflammatory illness. Pregnancies were uneventful, all reaching full term and normal 
birth weight; mean 3.58kg (range 3.3-4.48kg).  Data on mode of delivery were available for five 
cases, with three cesarean sections and two vaginal deliveries.  
Duration of treatment and its relation to pregnancy differed in each case; two babies were 
conceived on canakinumab which was discontinued as soon as pregnancy was confirmed in the 
1st trimester, at 8 weeks and 12 weeks respectively.  Two mothers switched to anakinra, at 8 and 
36 weeks, and one was treated from before conception to term with 300mg canakinumab 8 
weekly, with last dose at 36/40.   
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Five babies were born to three fathers who were on long term treatment (median 24  (Range 6-
73) months) at time of conception for CAPS (n=2) and TRAPS (n=1).  This included two fathers 
who had CAPS complicated by AA amyloidosis and prior to effective treatment with anti IL-1 
agents (one each of anakinra and canakinumab) were confirmed infertile with severe 
oligospermia. 66% of the offspring were male (Table 4).  At mean follow-up of 6.83 (range 4-10) 
years, no growth or developmental abnormalities have been identified.  
Four babies were breast fed by mothers’ prescribed regular canakinumab. There were no 
reported serious infections and no developmental abnormalities at a mean follow-up of 2.2 years 
(range 5 months to 4 years).  
 
Anakinra 
29 pregnancies were exposed to anakinra in total, 23 through maternal exposure, resulting in the 
births of 28 infants (Table 3).  Mean maternal age was 29 years (range 20-38 years).  Maternal 
diagnoses were CAPS (12), adult onset Still’s Disease (AOSD) (4), FMF (3), TRAPS (2), pericarditis 
(1), and Cogan syndrome (1). All patients were in complete clinical and biochemical remission 
with exception of the 2 women with AOSD and Cogan syndrome, whose diseases were less well 
suppressed.  39% of mothers took anakinra continuously from before conception to delivery and 
during the puerperium. Three mothers conceived on anakinra but discontinued it when 
pregnancy was confirmed at up to 16/40. Three women started anakinra during pregnancy; two 
were switched to anakinra from canakinumab before 8/40, and one started at 22/40 due to active 
inflammatory disease.   A single miscarriage occurred, at 12 weeks gestation in a 25-year-old 
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female with refractory Cogan syndrome; she had achieved only a partial clinical and biochemical 
response despite dose escalation of anakinra to 200mg daily, which she had taken before 
conception and throughout the first trimester.  
A 29 year old female with AOSD, who had a history of two miscarriages at 10 and 13 weeks and 
an ectopic pregnancy, delivered a healthy girl at 38 weeks, having started anakinra 100mg before 
conception and continued it until 25/40.  
There was no history of infection in either the mothers or babies exposed to anakinra.  Where 
data were available regarding mode of delivery, seven (60%) babies were born via spontaneous 
normal delivery, four by cesarean section and two deliveries were induced at between 35+1 (for 
vaginal bleeding)- 41+1 weeks.  
All babies were born healthy with normal APGAR scores at 10 minutes and 50% were male. There 
was a single case of ectopic neurohypophysis with growth hormone deficiency and left renal 
agenesis in a baby boy born to a mother aged 30 years with AOSD.  It was the mother’s first 
pregnancy and she had corticosteroid refractory disease at the time of conception.  Anakinra 
therapy began at nine weeks gestation and continued until elective caesarean section at 38+1/40 
with excellent clinical and biochemical response.  The infant was developing normally at time of 
last contact aged 15 months.  
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Ten babies were breast fed by mothers taking anakinra for up to ten months with no reported 
infections or developmental abnormalities.  
Six babies were conceived whilst their fathers were taking anakinra.  There were no congenital 
or developmental abnormalities reported at follow-up of between 4 weeks and 8 years (Table 4).  
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DISCUSSION 
 
Potential parents greatly wish to minimize any risks to a future child and the decision to proceed 
with pregnancy on novel therapies of uncertain safety remains extremely difficult for the family 
and their physicians.  SAIDS frequently relapse rapidly after treatment withdrawal and many 
patients on long-term anti-IL-1 agents can only tolerate very brief suspension of treatment. 
Consequently simple symptomatic management throughout pregnancy is not generally feasible. 
In addition, uncontrolled inflammatory activity has deleterious effects on fertility and pregnancy 
outcomes; poorly controlled FMF is associated with a modest increase in fetal loss, preterm 
delivery, low birth weight and Caesarian section.(6) Male fertility is also reduced in the presence 
of chronic inflammation and testicular AA amyloidosis is a recognized cause of azoospermia.(7)  
In two fathers reported here, long term control of CAPS, first with anakinra and then 
canakinumab, resulted in regression of amyloid that was evident on serial SAP scintigraphy, 
resolution of associated nephrotic syndrome and reversal of previous infertility. Uncontrolled 
inflammatory disease carries its own risks to fertility, the fetus and the mother and these should 
be included in preconception parental counselling  
The data reported here substantially increases the evidence base for anakinra and canakinumab 
use prior to conception, during pregnancy and breast-feeding. They include the first human data 
on canakinumab-exposed pregnancies and the largest reported series receiving anakinra. In 
general the data are reassuring for both agents and for paternal and maternal exposure. There 
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are no data on rilonacept and we would not advocate its use in pregnancy based on teratogenicity 
in animals. 
There was a single case of congenital abnormality in a boy born to a mother with active refractory 
AOSD.  AOSD is the most heterogeneous of diseases included in the study with no known genetic 
susceptibility and its diagnosis is based on relatively loose criteria.  The patient had active disease 
at the time of conception, and had had considerable prior treatment including azathioprine and 
high-dose corticosteroids. Anakinra was initiated at nine weeks gestation.  Prenatal screening 
identified an ectopic neurohypophysis, resulting in growth hormone deficiency, and a single 
kidney. Renal tract abnormalities, including unilateral renal agenesis, have been reported to 
occasionally occur in individuals with ectopic neurohypophysis.(8) Moreover, the latter condition 
has been associated with gene variants in the sonic hedgehog (SHH) pathway, (9) and SHH 
pathway molecules are present in the developing human renal tract.(10)  Our case is important, 
as it is now the second report of renal agenesis in anakinra-exposed pregnancies.  Chang et al 
reported a twin pregnancy in which one fetus died in utero and had bilateral renal 
agenesis.(11) The surviving twin had no developmental abnormality and was well at last reported 
follow-up. The mother was 19 years old in her first pregnancy having received anakinra for eight 
years for CAPS. She was prescribed a higher dose of anakinra at conception than in our cohort, 
at start of pregnancy 239 mg, increasing to 300 mg daily. She also had a history of diabetes 
mellitus both this and the twin pregnancy are knownrisk factors for renal tract abnormalities.(12)  
Wiesel et al reported unilateral renal agenesis in 58 of 709,030 live births, stillbirths, and induced 
abortions, and 95 cases of bilateral agenesis in the same population.(13) Therefore, one case of 
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either renal malformation among 36 anakinra-exposed fetuses is higher than the expected 
frequency. Whilst experimental evidence for a direct role of the IL-1 axis in normal or abnormal 
renal development is currently lacking, reassuringly in an experimental murine model of a hostile 
uterine environment in which IL-1 is known to be elevated, inhibition of IL-1 may improve the 
likelihood of implantation and prevent pregnancy loss.(14), (15) Future research should seek 
whether IL-1 and its receptors are expressed in the normal and malformed renal tract, and the 
spatial and temporal relation of these molecules to those in the SHH pathway. 
The current study has a number of limitations; it was retrospective and is therefore prone to 
errors such as recall bias and variable data collection between centers. Nonetheless this 
represents the best data to date and highlights the pressing need for prospective data collection, 
using existing registries such as EUROFEVERS (https://www.printo.it/eurofever/) or the British 
Society of Rheumatology Biologics Register (BSRBR) 
(http://www.rheumatology.org.uk/resources/bsr_biologics_registers/), and rapid feedback of 
relevant information to our patients and their families.  
Overall the data show that the use of anakinra and canakinumab appears well tolerated, and 
efficacious during pregnancy and in males at conception.  Serious questions remain about the 
increased incidence of renal tract abnormalities seen and suggests that this should be discussed 
with all potential parents at preconception counselling.  We acknowledge that reported numbers 
remain small with 43 maternal cases in the literature (summarized in Table 5). 
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Our current practice is to advise that paternal use of IL-1 antagonists at conception appears safe, 
albeit based on limited clinical experience. We offer counseling for prospective parents before 
conception in all cases and discuss the option of temporarily ceasing IL-1 inhibiting treatment, 
whilst highlighting that this approach is often poorly tolerated and may carry risks to conception 
and fetal growth associated with uncontrolled inflammation. For women who are unable or do 
not wish to stop IL-1 antagonists, there are two options. First, not to conceive a child, and second, 
to proceed with conception and pregnancy following an informed discussion on risk-benefit.  For 
women who do wish to become pregnant, we favor use of anakinra at the current time, based 
on clinical experience to date, its homology with natural IL-1Ra, and its short elimination half-life. 
A theoretical concern regarding canakinumab is the possibility of active transport of IgG 
monoclonal antibodies across the placenta from 30 weeks, and combined with the prolonged 
half-life of immunoglobulins in neonates, we suggest that canakinumab should not be 
administered from 22 weeks gestation in line with EULAR recommendations, and should be 
avoided where possible.  
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Table 1: Licensed Interleukin-1 Antagonists and evidence for their use in pregnancy and 
lactation 
IL-1 Antagonist Half-life 
 
Animal data Human Data FDA Pregnancy 
Category† 
Lactation 
Anakinra  
(Kineret®, Sobi) 
recombinant human IL-1 
receptor antagonist  
(IL-1 Ra) 
5.7 hours 
(16) 
No evidence of impaired fertility 
or fetal harm in rats or rabbits at 
doses > x25 human dose 
5 completed pregnancies 
in Adult Onset Stills 
Disease (AOSD) (17, 18)  
9 completed pregnancies 
in CAPS (11) 
See Table 5 
 
B IL-1 Ra is a normal 
component of breast milk. 
Single report; No adverse 
outcomes reported (18) 
Canakinumab (Ilaris®, Novartis) 
human IgGkappa monoclonal 
antibody to IL-1Beta 
29 
Days 
(3) 
No fetal abnormalities in 
Marmosets, delayed cranial 
ossification in mice but no 
teratogenicity. (19)  
 
No data C No data 
Rilonacept 
(ARCALYST®, Regeneron 
Pharmaceuticals) Dimeric, 
glycosylated fusion protein 
composed of the extracellular 
domains of the interleukin 1 
receptor and an accessory 
protein IL-1-RAcP fused to the Fc 
domain of human IgG1  
8.6 days  
(20)  
 
Teratogenic in Cynomolgus 
monkeys; increased incidence of 
stillbirths, lumbar ribs, fusion of 
ribs and thoracic vertebral bodies 
and arches 
(21) 
 
No data C No data 
 
Table 1: †The United States Food and Drug Administration (FDA) Pregnancy Category B: animal 
studies have failed to demonstrate a risk to the fetus, there are no adequate studies in pregnant 
women; Category C: There are no adequate and well-controlled studies in pregnant women. 
Based on animal data, may cause fetal harm.  
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Table 2 Canakinumab Exposed Pregnancy and Breast Feeding outcomes  
 
 
 
Maternal 
age at 
pregnancy 
(years) 
Diagnosis Dose and 
duration of 
canakinumab 
Dates and 
mode of 
delivery 
Birth 
weight Kgs 
APGAR 
Score 
Gender of 
Infant 
Development Age at 
last 
contact 
Mode of 
feeding 
25 
 
CAPS 150mg 8 weekly 
PC to 8/40 
38 
El-CS† 
 
3.54 10 Male Normal 3 years Bottle 
32* 
 
CAPS 150mg 8 weekly 
PC to PPT (12/40) 
40 
VD 
4.48 10,10,10 Female Normal 5 months Breast 
24* 
 
CAPS 150mg  
8 weekly until 
36/40 
40 
NR 
3.57 NR Male Normal 7 days NR 
16 CAPS 120mg single 
dose post  
conception prior 
to PPT 
38 
NR 
3.29 9,9,10 Male Normal 4 years Breast 
21 Un-SAID 300mg 8 weekly 
PC to D 
(last dose at 
36/40 
39 
VD 
NR 10,10,10 Male Normal 1 year NR 
21 FMF 150mg 4 weekly 
PC-D 
37 
El-CS‡ 
 
 
3.3 “Normal” Male Normal 11 
months 
Breast 
27 FMF 150mg 8 weekly 
PC to PPT 4/40 
40 
El-CS‡ 
 
3.3 “Normal” Female Normal 3.5 years Breast 
26† Cogan 
Syndrome 
150mg 4 weekly 
PC-6/40 
Miscarriag
e  
6/40 
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Table 2: Kgs Kilograms, Un-SAID uncharacterized systemic autoinflammatory disease, PC prior to 
conception, PPT confirmation of pregnancy (positive pregnancy test) , D delivery, VD vaginal 
delivery, I-VD induced vaginal delivery, EM-CS emergency cesarean section, EL-CS elective 
cesarean section, NR not reported, CAPS Cryopyrin Associated Periodic Fever Syndromes, FMF 
Familial Mediterranean fever, AOSD Adult Onset Stills Disease, TRAPS TNR Receptor Associated 
Periodic Fever Syndrome,† due to gestational diabetes ‡ due to patient choice, * denotes patient 
who received both canakinumab and anakinra during same pregnancy,  †denotes same patient 
who received both canakinumab and anakinra in two separate pregnancies both resulting in 
miscarriage (see also Table 3). 
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Table 3 Anakinra Exposed Pregnancy and Breast Feeding Outcomes 
 
Maternal age 
at pregnancy 
(years) 
Diagnosis Dose and 
duration of 
anakinra 
Dates 
(weeks) & 
Mode of 
delivery 
Birth 
weight 
(kg) 
APGAR Gender Development Age at last 
contact 
Mode of 
Feeding 
29 
 
CAPS 50mg alt/days 
PC to D 
39 
I-VD 
3.94 9,9,9 Male Normal 4 years Bottle 
32 
 
CAPS 50mg alt/days 
PC to D 
39 
VD 
NR NR Female Normal 2 years Bottle 
30 
 
CAPS 100mg daily 
PC to D 
41+1 
VD 
3.6 9,9,10 Male Normal 2 years Breast 
32* 
 
CAPS 100mg daily 
PPT to D 
40 
VD 
4.48 10 Female Normal 5 
Months 
Breast 
24* 
 
CAPS 100mg daily  
36/40  
to D 
40 
NR 
3.57 NR Male Normal 7 days NR 
20 CAPS 100mg 
PC to PPT 
36+6 
NR 
2.83 10,10,10 Male Normal 10 weeks Bottle 
24 CAPS 100mg 
PC to D 
38+6 
EM-CS1 
NR NR NR Normal 6 months NR 
34 CAPS 100mg daily  
PC  to 6/40 
40 
El-CS2 
NR NR Male Normal 18 months NR 
25 CAPS 100mg daily  
PC to D 
NR NR NR Male Normal 8 years Breast 
10/12 
35 CAPS 100mg daily 
Dates NR 
40+1 
NR 
NR NR Female Normal NR NR 
38 CAPS 100mg 
Dates NR 
NR NR NR Female Normal NR NR 
28 CAPS 100mg 
Dates NR 
NR NR NR Female Normal NR NR 
33 FMF 100mg daily 36+1 2.17 8 Male Normal 2 years Breast 
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PC-D El-CS3 
28 FMF 100mg daily 
12/40 to D 
40 
VD 
3.17 10 Female Normal 19 months Breast 3/12 
24 FMF 100mg daily 
PC-D 
36 
VD 
1.6 7 Female Normal 9 months Breast 
38 Idiopathic 
Pericarditis 
100mg daily 
PC to PPT 
38+2 
VD 
2.93 8,9,9 Male Normal 12 weeks Bottle 
29 AOSD 200-300mg daily 
PC-16/40 
37 2.45 9 Female Normal 10 months Bottle 
31 AOSD 100mg daily 
22/40-32/40 
Then alt days to 
33/40 
35+1 
NR 
2.02 9 Male Normal 18 months Breast 
30 AOSD 100 mg daily 
9/40 to D 
38+1 
El-CS2 
NR 7,8,9 Male - Left  Renal Agenesis 
- Ectopic 
Neurohypophysis with 
growth hormone 
deficiency 
1 year 
3months 
Breast 3/12 
29 AOSD 100mg daily 
NR 
38 
VD 
3.06 Normal Female Normal 9 months Breast 
29 TRAPS 100mg daily 
PC to D 
41 
I-VD 
3.23 9,9,9 Male Normal 8 months Breast 
29 TRAPS 100mg 
PC to D 
NR NR NR Female Normal NR NR 
25† Cogan 
Syndrome 
200mg daily 
PC-12/40 
Miscarriage 
12/40 
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Table 3: PC prior to conception, PPT confirmation of pregnancy (positive pregnancy test) , D delivery, VD vaginal 
delivery, I-VD induced vaginal delivery, EM-CS emergency cesarean section, EL-CS elective cesarean section, NR not 
reported, CAPS Cryopyrin Associated Periodic Fever Syndromes, FMF Familial Mediterranean fever, AOSD Adult 
Onset Stills Disease, TRAPS TNR Receptor Associated Periodic Fever Syndrome, mg miligrams, kg kilograms, 1failure 
to progress, 2patient choice, 3per vaginal bleed started at 34/40,   * denotes patient who received both canakinumab 
and anakinra during same pregnancy,  †denotes same patient who received both canakinumab and anakinra in two 
separate pregnancies both resulting in miscarriage (see also  Table 2). 
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Table 4 Pregnancies with Paternal Exposure to Anakinra or Canakinumab at conception:  
 
Diagnosis  Number of 
offspring 
exposed 
Drug/Dose Drug 
duration 
prior to 
conception 
(months) 
Congenital 
Abnormalities 
Developmental 
Abnormalities 
Gender Age at last 
contact 
AOSD  1 Anakinra 
100mg daily 
Not known None None Female 4 weeks 
AOSD 
 
1 Anakinra 
100mg daily  
Not Known None None Female 10 months 
CAPS  3 Canakinumab 
150mg 8 
weekly 
248 
75 
None 
None 
None 
None 
None 
None 
Male 
Male 
Female 
10 years 
8 years 
4 years 
CAPS  1 Anakinra 
100mg daily 
25 None None Male 8 years 
CAPS 1 Canakinumab 
150mg 8 
weekly 
23 None None Male 7 years 
TRAPS 2 Anakinra 
100mg 
alternate days 
 
3 
57 
None 
None 
None 
None 
Male 
Female 
5 years 
6 months 
TRAPS  1 Anakinra 
100mg daily 
66 None None Male 16 months 
TRAPS  1 
(IVF) 
Canakinumab 
150mg 8 
weekly 
24 None None Female 2 years 
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Table 4 Legend:  
AOSD Adult Onset Stills Disease, CAPS Cryopyrin Associated Periodic Fever Syndromes, TRAPS Tumour 
Necrosis Factor Receptor Associated Periodic Fever Syndrome, IVF In Vitro Fertilization.  
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Table 5: Summary of previously published data on anakinra use in pregnancy   
Reference Maternal 
Diagnosis 
 
Treatment and 
dose 
Delivery Birth 
weight 
(kgs) 
APGAR 
Score 
Gender Development Duration of 
follow up 
Method of 
feeding 
Berger 2009 (18) 
 
AOSD Anakinra 
100mg daily 
2 years prior to 
and through 
pregnancy and 
delivery 
VD 
 
2.7 kg 7,8,9 Female Normal 4 months Breast  
Fischer Betz (22) 
Case 1 
AOSD Anakinra 100mg 
daily, 1 year prior 
to pregnancy and 
throughout 
VD 
39/40 
3.1 kg NR Male Normal NR Bottle 
Fischer Betz  
Case 2 
AOSD Anakinra 
100mg daily 
12/40 onwards 
CS 
36/40 
2.8 kg NR Male Normal NR Bottle 
Chang 2014(11) 
Case 1 
CAPS Anakinra VD 
41/40 
3.74 kg NR NR NR NR Bottle 
Chang 2014 
Case 2 
CAPS Anakinra VD  
41/40 
3.63 kg NR NR NR NR Bottle 
Chang 2014 
Case 3 
CAPS Anakinra  VD 
38/40 
3.40 kg NR NR NR NR Breast  
3 months 
Chang 2014 
Case 4 
CAPS Anakinra VD 
37/40 
3.46 kg NR NR NR NR Bottle 
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Chang 2014 
Case 5 
CAPS Anakina  VD 
37.5/40 
2.98 kg NR NR NR NR Bottle 
Chang 2014 
Case 6 
CAPS Anakinra VD 
39/40 
3.35 kg NR NR NR NR Bottle 
Chang 2014 
Case 7 
CAPS Anakinra CS 
40/40 
4.14 kg NR NR NR NR Breast 
1Year 
Chang 2014 
Case 8* 
CAPS Anakinra VD 
38.7/40 
2.64 kg NR NR NR NR Breast 
< 1 month 
Chang 2014 
Case 9 
CAPS Anakinra CS 
“term” 
3.52 kg NR NR NR NR Bottle 
 
 
 
 
 
 
 
 
 
 
Table 5: CAPS Cryopyrin Associated Periodic Syndrome, VD Vaginal Delivery, CS Cesarean Section, NR not 
recorded * twin dichorionic-diamniotic pregnancy with fetal demise of one fetus with bilateral renal 
agenesis, surviving twin had no congenital abnormality.  
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